Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Grillo

Showing results (31-40 of 84) with videos related to

Pageof 9
Sort By:
Cancer Treatment Reports|December 1, 1983
Phase II study of amsacrine gluconate in refractory leukemiaG A Omura, E F Winton, W R Vogler, et al.
Leukemia|July 30, 2003
Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: final report on safety and efficacyL E van der Kolk, A J Grillo-López, J W Baars, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1986
Amsacrine-associated cardiotoxicity: an analysis of 82 casesR B Weiss, A J Grillo-López, S Marsoni, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1989
Phase I clinical and pharmacologic trial of trimetrexate in combination with 5-fluorouracilG R Hudes, F LaCreta, R J DeLap, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1987
A phase II trial of diaziquone in patients with head and neck cancerF Muñiz, E Vélez-García, J A Neidhart, et al.
Journal of Neuro-Oncology|January 1, 1985
Phase II evaluation of diaziquone (CI-904, AZQ) in the treatment of human malignant gliomaJ Maral, M Poisson, B F Pertuiset, et al.
Revista Espanola De Cardiologia (English Ed.)|April 30, 2014
Cardiac manifestations in myotonic dystrophy type 1 patients followed using a standard protocol in a specialized unitMaría Facenda-Lorenzo, Julio Hernández-Afonso, Marcos Rodríguez-Esteban, et al.
Seminars in Oncology|November 24, 1999
Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphomaA J Grillo-López, C A White, C Varns, et al.
British Journal of Haematology|February 15, 2002
Complement activation plays a key role in the side-effects of rituximab treatmentL E van der Kolk, A J Grillo-López, J W Baars, et al.
NCI Monographs : a Publication of the National Cancer Institute|January 1, 1987
Trimetrexate: clinical development of a nonclassical antifolateP J O'Dwyer, R J DeLap, S A King, et al.
Pageof 9

Showing results (31-40 of 84) with videos related to

Sort By:
Pageof 9
Cancer Treatment Reports|December 1, 1983
Phase II study of amsacrine gluconate in refractory leukemiaG A Omura, E F Winton, W R Vogler, et al.
Leukemia|July 30, 2003
Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: final report on safety and efficacyL E van der Kolk, A J Grillo-López, J W Baars, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1986
Amsacrine-associated cardiotoxicity: an analysis of 82 casesR B Weiss, A J Grillo-López, S Marsoni, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1989
Phase I clinical and pharmacologic trial of trimetrexate in combination with 5-fluorouracilG R Hudes, F LaCreta, R J DeLap, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1987
A phase II trial of diaziquone in patients with head and neck cancerF Muñiz, E Vélez-García, J A Neidhart, et al.
Journal of Neuro-Oncology|January 1, 1985
Phase II evaluation of diaziquone (CI-904, AZQ) in the treatment of human malignant gliomaJ Maral, M Poisson, B F Pertuiset, et al.
Revista Espanola De Cardiologia (English Ed.)|April 30, 2014
Cardiac manifestations in myotonic dystrophy type 1 patients followed using a standard protocol in a specialized unitMaría Facenda-Lorenzo, Julio Hernández-Afonso, Marcos Rodríguez-Esteban, et al.
Seminars in Oncology|November 24, 1999
Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphomaA J Grillo-López, C A White, C Varns, et al.
British Journal of Haematology|February 15, 2002
Complement activation plays a key role in the side-effects of rituximab treatmentL E van der Kolk, A J Grillo-López, J W Baars, et al.
NCI Monographs : a Publication of the National Cancer Institute|January 1, 1987
Trimetrexate: clinical development of a nonclassical antifolateP J O'Dwyer, R J DeLap, S A King, et al.
Pageof 9